On March 28, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported three data presentations at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in Washington, D.C (Press release, Ignyta, MAR 28, 2017, View Source [SID1234518298]). Schedule your 30 min Free 1stOncology Demo! Two poster presentations will include new preclinical data on the immuno-oncology therapeutic capabilities of RXDX-106, which represents a novel class of immunomodulatory agents that appears to restore innate immunity in preclinical models via potent inhibition of the TYRO3, AXL and MER (or TAM) family of receptors.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, the company will present its first ever data from molecularly targeting hematological malignancies with entrectinib – an orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions – in previously unexplored, molecularly defined acute myeloid leukemia (AML). Entrectinib is currently being studied in a registration-enabling Phase 2 clinical trial known as STARTRK-2.
"We are excited to participate in this year’s AACR (Free AACR Whitepaper) Annual Meeting and provide key program updates on multiple compounds from across our precision medicine pipeline," said Pratik Multani, M.D., Ignyta’s Chief Medical Officer. "In particular, we look forward to highlighting RXDX-106’s promising immuno-oncology potential and our first entrectinib data in hematological malignancies."
Details of the presentations are as follows:
Poster Presentations:
RXDX-106
Title:
Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor (Abstract number 4698)
Date/Time: Tuesday, April 4, 2017, 1:00 PM – 5:00 PM ET
Title:
RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor, demonstrates efficacy in TAM-driven tumors (Abstract number 4191)
Date/Time: Tuesday, April 4, 2017, 1:00 PM – 5:00 PM ET
Entrectinib
Title:
Anti-tumor activity of entrectinib, a highly potent pan-TRK, ROS1 and ALK inhibitor, in molecularly defined acute myeloid leukemia (Abstract number 5158)
Date/Time: Wednesday, April 5, 2017, 8:00 AM – 12:00 PM ET
A copy of the posters will be made available during the sessions in the Scientific Presentations section of the company’s website at View Source, and will be archived and available at that site.